However, research has identified several autoantibodies that may play a role in the pathogenesis of MS or serve as biomarkers for disease subtypes, including myelin oligodendrocyte glycoprotein (MOG) antibodies identified in a subset of patients, particularly those with optic neuritis, transverse myelitis, and some forms of demyelinating disease; antibodies against neurofascin proteins (NF155, NF186), found in more aggressive forms of MS and those exhibiting peripheral nerve involvement; potassium channel KIR4.1 antibodies; and anti-nuclear antibodies (ANAs), which are non-specific. This evidence concerns the gene MOG and transverse myelitis.